TIDES USA 2025: Introducing Oligonucleotide and Peptide Reagent Solutions

Featured Speaker

Join Colin Smith, Aurorium's Innovation Leader in Pharma, on May 21st at 3.40 PM PDT for his presentation, Overcoming Impurities in Therapeutic APIs: Transforming Reagent Solutions for Solid and Liquid Phase TIDES Synthesis, where he will discuss next-generation purity solutions for peptide and oligonucleotide API manufacturers. Learn how Aurorium's reagents optimize SPPS and LPPS to reduce impurities and improve drug efficacy and patient outcomes.

In his role at Aurorium, Colin leads innovation efforts to develop high-purity products tailored for the pharmaceutical industry.

His expertise includes developing innovative synthesis methodologies for small heterocycles and leading the development and commercial production of drug protein conjugates.

Why Aurorium?

Aurorium provides chemical solutions with expertise in synthetic chemistry and purification. The Haelium™ line supports oligonucleotide and peptide therapeutics manufacturing with high-quality reagents, excipients, and technical support.

Aurorium is setting a new benchmark in the TIDES space through world-class innovation and execution:

• Expertise in pyridine chemistry and purification.
• Large scale, US-based manufacturing sites for scale and precision.
• Working as an extension of our customers to overcome both emerging and long-standing hurdles in TIDES.

Connect with Aurorium at TIDES

Connect with the Aurorium team at TIDES to discuss the Haelium products or Colin's presentation - look out for us walking the floor. Get more details about the TIDES USA: Oligonucleotide and Peptide Therapeutics event and view the full agenda.

We look forward to seeing you in San Diego!